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Abstract Immunoglobulin G (IgG) represents the major frac-
tion of antibodies in healthy adult human serum, and devia-
tions from physiological levels are a generic marker of disease
corresponding to different pathologies. Therefore, screening
methods for IgG evaluation are a valuable aid to diagnostics.
The present work proposes a rapid, automatic, and miniatur-
ized method based on UV-vis micro-bead injection spectros-
copy (μ-BIS) for the real-time determination of human serum
IgG with label-free detection. Relying on attachment of IgG in
rec-protein G immobilized in Sepharose 4B, a bioaffinity col-
umn is automatically assembled, where IgG is selectively
retained and determined by on-column optical density mea-
surement. A Bdilution-and-shoot^ approach (50 to 200 times)
was implemented without further sample treatment because
interferences were flushed out of the column upon sample
loading, with minimization of carryover and cross-
contamination by automatically discarding the sorbent
(0.2 mg) after each determination. No interference from hu-
man serum albumin at 60 mg mL−1 in undiluted sample was
found. The method allowed IgG determination in the range
100–300 μg mL−1 (corresponding to 5.0–60 mg mL−1 in un-
diluted samples), with a detection limit of 33 μg mL−1
(1.7 mg mL−1 for samples, dilution factor of 50). RSD values
were < 9.4 and < 11.7%, for intra and inter-assay precision,
respectively, while recovery values for human serum spiked
with IgG at high pathological levels were 97.8–101.4%.
Comparison to commercial ELISA kit showed no significant
difference for tested samples (n = 8). Moreover, time-to-result
decreased from several hours to < 5 min and analysis cost
decreased 10 times, showing the potential of the proposed
approach as a point-of-care method.
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Introduction
Immunoglobulins G (IgG) are the major group of antibodies
of healthy adult human serum, ranging from 7 to 18 mg mL−1
[1, 2]. This group of proteins is a valuable serum biomarker
for several pathologies that affect directly or have repercus-
sions in the immune system. For instance, decreased levels of
IgG may be associated with primary antibody deficiency,
protein-losing enteropathies, nephrotic syndrome, or iatrogenic
hypogammaglobulinemia as a consequence of immunosuppres-
sant, anti-convulsant, or cytotoxic therapies [3–7]. The level of
serum IgG is also a valuable predictor for the risk of infection in
transplant recipients [8–10]. Moreover, high IgG levels are indi-
cators of autoimmunity (e.g., demyelinating diseases, lupus ery-
thematosus), chronic infection, liver diseases (e.g., autoimmune
hepatitis), and lymphoproliferative disorders (e.g., multiple my-
eloma) [3, 11–14]. The early diagnosis of these conditions is a
key factor to minimize the risk of permanent organ damage and
to proceed with adequate therapy, accounting for less morbidity
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and mortality [14, 15]. Metabolic abnormalities (e.g., metabolic
syndrome, obesity), smoking, and drinking have also been
shown to have a significant impact on IgG levels [1].
The determination of serum IgG level is currently performed
by enzyme-linked immunosorbent assay (ELISA), single radial
immunodiffusion (SRID), or immuno-nephelometric/turbidimet-
ric methods [16–19]. These batch-wise assays are generally time-
consuming and laborious, particularly when it comes to immune
recognition schemes because they involve convection-based
mass transport of the reagents through the reactionmedia, requir-
ing long incubation times. In fact, ELISA and SRID are multi-
step complex procedures that usually provide large time-to-result
intervals (typically up to 6 h for the ELISA and 14–24 h for the
SRID assay) [20, 21]. Furthermore, these methods can be highly
affected by operational errors and are prone to cross-
contamination problems that may occur during washing steps
or solution handling, particularly if performed manually.
ELISA methods are also highly affected by external conditions,
namely temperature, which can impair data validity, known as
the Bedge effect^ [22–24]. Another important aspect is the need
of enzyme/antibody conjugates that increase the cost of analysis.
As for turbidimetry/nephelometry-based methods, which have
been replacing SRID and ELISA in clinical analysis, the main
analytical issue is the presence of substances other than antigen-
antibody complexes that increase background light scattering or
that form precipitates, hampering IgG quantification and
affording overestimation [25]. This effect is especially relevant
in the presence of high concentrations of protein; thus, sample
cleanup steps are often required to minimize interferences.
Recently, label-free approaches have been proposed for the
determination of IgG in human serum based on mass spectrom-
etry [26], on magnetically assisted surface enhanced Raman
spectroscopy through a Fe3O4@Ag@streptavidin@anti-IgG
nanocomposite [27], on nanoporous hydrogel photonic crystal
structures containing immobilized protein A [28], on attenuated
total reflectance mid-infrared spectroscopy coupled to multivari-
ate calibration [29], and on voltammetric detection of IgG bind-
ing to reduced graphene oxide@multiwalled carbon
nanotube@palladium@anti-IgG nanoparticles [30].
Nevertheless, these methods still require non-portable equipment
[26], cumbersome synthesis of materials [28, 30], or advanced
data processing [29].
In this context, UV-vis Bead Injection Spectroscopy has
been applied to bioanalysis through the combination of flow
analysis with on-column optical density measurements to fol-
low bioligand interactions occurring on surfaces [31–35]. In
particular, the mesofluidic Lab-on-Valve (LOV) platforms are
useful for the miniaturization of bioanalytical assays, namely
through micro-Bead Injection Spectroscopy (μ-BIS) due to
their versatility and green chemistry features, as it downscales
the consumption of sample and reagents [36].
The applicability of the μ-BIS-LOV strategy for the real-
time monitoring of the immobilization of different proteins on
agarose beads was first demonstrated by Ruzicka and co-
workers [37], and it has also been used for on-column monitor-
ing of IgG retention in protein G-Sepharose® beads [31]. The
use of beads with adequate optical properties allowed the eval-
uation of binding of IgG from different species (human, rabbit,
and horse), but it has not been applied to real samples or to IgG
quantification. The field of application of the μ-BIS-LOV strat-
egy was enlarged when Decuir and co-workers [38] performed
the capture and simultaneous quantification of biotinylated
DNA on solid surfaces. So far, this technique has been
employed for the evaluation and optimization of bioaffinity
processes, but its potential for clinical applications and point-
of-care testing for biomarker assessment remains underexploit-
ed. Hence, the aim of this work is the development and appli-
cation of μ-BIS-LOV for the automated, miniaturized, and di-
rect quantitative determination of IgG in human serum with
label-free detection. For this, a molecular recognition strategy
will be implemented, using commercially available protein G
immobilized in highly cross-linked agarose.
Experimental
Chemicals
All chemicals used were of analytical reagent grade with no
further purification. Water from arium water purification sys-
tems (resistivity > 18 MΩ cm, Sartorius, Goettingen,
Germany) was used for the preparation of all solutions.
Recombinant Protein G-Sepharose® 4B (no. 10-1241) and
streptavidin agarose (no. S951) were purchased from
Thermo Fisher Scientific (Rockford, IL, USA). Sepharose®
CL-4B (no. CL4B200), human IgG standard (no. I2511), and
human serum albumin (no. A1887) were obtained from
Sigma-Aldrich (St. Louis, MO, USA). HiTrap® Protein A
HP columns (no. 17-0403-01) were acquired from GE
Healthcare (Chicago, IL, USA). The human IgG ELISA kit
(no. RAB0001) used for method validation was also pur-
chased from Sigma-Aldrich.
IgG standard solutions (100–400 μgmL−1) and diluted sam-
ples (1:40 to 1:100 times) were prepared in PBS buffer
(140 mM NaCl, 16 mM Na2HPO4, 2 mM KH2PO4, 16 mM
EDTA-2Na, pH 7.4). This buffer was also used as carrier solu-
tion in the flow system. Prior to use, beads were washed with
PBS (pH 7.4) and recovered by centrifugation (3326×g, 4 °C,
10 min). These operations were performed four times each.
μ-BIS-LOV configuration and analytical procedure
The LOV equipment (MicroSIA, FIAlab Instruments, Inc.,
Bellevue, WA, USA), depicted in Fig. 1, comprises a
1000-μL bi-directional syringe pump, connected to a two-
way valve, a holding coil, and a LOV platform mounted atop
a six-port multi-position valve. It was configured for μ-BIS
with the following port assignments: (1) beads, (2) waste, (4)
flow cell, and (6) sample/standard. Ports 3 and 5 were not
used. The flow cell (optical path 1.6 mm) was illuminated
by a 600-μm fiber-optic cable connected to the light source
(deuterium-halogen light source model DH-2000, Top Sensor
Systems, Eerbeek, The Netherlands). Emerging radiation was
collected by another 600 μm fiber optic cable, connected to a
USB4000-UV-vis CCD spectrometer (Ocean Optics, El
Dorado Hills, CA, USA). A PEEK plug (0.13 mm ID, 3 mm
long) was placed immediately below the light beam to retain
the beads inside the flow cell, allowing the liquid to flow out.
The systemwas operated at room temperature, controlled by a
personal computer running FIAlab software (FIAlab
Instruments, Inc.), version 5.9.320.
The analytical cycle for bead column assembly and IgG de-
termination is detailed in Table 1. For each determination, anal-
ysis started by packing a fresh immunoaffinity column inside the
flow cell (Table 1, routine A). The bead suspension placed in port
1 was dispersed by flushing 4 μL of PBS into this port followed
Table 1 μ-BIS-LOVanalytical cycles for the determination of total human IgG
Step LOV valve position Flow rate (μL s−1) Volume (μL) SP valve positiona Description
Routine A: packing of bead column (30 s)
I 2 200 600 In Aspirate carrier into syringe
II 1 3 4 Out Flush and disperse solid phase
III 1 5 10 Out Aspirate beads into central channel
IV 4 5 8 Out Send beads to the flow cell
V 2 200 400 Out Discard excess of beads to waste
VI 4 10 194 Out Conditioning of bead column
Routine B: IgG quantification (131 s)
VII 2 200 800 In Aspirate carrier into syringe
VIII 4 1 20 Out Acquire reference scan
IX 6 3 20 Out Aspirate sample into HC
X 4 1 100 Out Signal acquisition while sending HC content to the flow cell
Routine C: removal of bead column (28 s)
XI 4 100 200 Out Aspirate column beads into the central channel
XII – 100 800 In Aspirate carrier into syringe
XIII 2 200 1000 Out Discard beads
XIV – 100 1000 In Aspirate carrier into syringe
XV 4 400 1000 Out Wash flow cell
a BValve Out^ position connects the syringe pump (SP) to the LOV central channel. BValve In^ position means that the syringe pump is connected to the
carrier reservoir
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Fig. 1 μ-BIS-LOV configuration
for on-column quantification of
total human serum IgG. SP sy-
ringe pump, SV solenoid valve
connected to the syringe pump,
HC holding coil, LS light source,
CCD spectrometer, S sample/
standard,W waste. PBS buffer
(pH 7.4) was used as carrier
by immediate aspiration of 10 μL of the suspension, at a low
flow rate (3–5 μL s−1). Eight microliters of the bead suspension
was then sent to the flow cell and conditioned with 194 μL of
PBS at 10 μL s−1. During routine B (Table 1), aiming at IgG
assessment, 20 μL of standard or sample previously diluted in
carrier was aspirated and flushed through the beads’ column at a
low flow rate (1 μL s−1) to allow IgG interaction with protein G.
The interaction/immobilization process is monitored by measur-
ing the optical density at 280 nm elicited through the solid sup-
port, that is the attenuation of light intensity caused both by
absorbance and light scattering of IgG present in samples. By
the end of each complete analytical cycle, the bead column was
discarded by back-aspiration at a high flow rate (100 μL s−1) and
the flow cell was washed (Table 1, routine C) and prepared for
the packing of a new column.
Method validation by microplate ELISA
For comparison purposes, the concentration of IgG in the serum
of eight healthy individuals was assessed by the developed μ-
BIS-LOVmethod and by the commercially available microplate
ELISA kit. This assay is based on human IgG antibody-coated
plate and detection by biotinylated human IgG, horseradish
peroxidase-streptavidin conjugate, and 3,3 ′ ,5,5 ′-
tetramethylbenzidine as colorimetric substrate. Sample prepara-
tion and ELISA procedures for total human IgG detection were
carried out according to manufacturer’s instructions. Absorbance
at 450 nm was measured using a Cytation3® microplate reader
(BioTek instruments, Winoosky, VT, USA) operated by Gen5
software. Paired t test was applied to compare the results obtained
using both methods.
Results and discussion
Development of μ-BIS-LOV method
The μ-BIS-LOV method for the determination of serum IgG
consisted on a bioaffinity separative approach using a solid
phase containing an active bioligand. Method development
was directed towards the establishment of a straightforward
procedure without any incubation periods or stopped-flow
steps in order to attain a high-throughput procedure.
Additionally, μ-BIS-LOV allows the analyte to be actively
flushed through the solid phase, so it does not rely on
convection-based diffusion. Hence, IgG deposition on the sol-
id phase was evaluated by direct, on-column UV-vis spectros-
copy (280 nm), as schematically depicted in Fig. 1.
It was possible to apply a continuous flow strategy for
sample injection setting the flow rate to the minimum achiev-
able by the LOV equipment with a 1-mL syringe (1 μL s−1).
Higher flow rates decreased the contact time between IgG and
the bioaffinity elements embedded in the bead column and,
thus, retention was lower (data not shown). Initially, two li-
gands (protein A and protein G) and three supports (Sepharose
CL-4B, Sepharose CL-6B, and streptavidin 4B Sepharose)
were evaluated. It was observed that the nature of the retaining
proteins embedded in the agarose column affected the stability
of the acquired signal during flow conditions. For instance,
Sepharose 4B containing either protein A or protein G pre-
sented different baseline profiles when 20 μL of buffer was
injected at 1 μL s−1, as shown in Fig. 2. The same experiment
was performed for protein A bound to Sepharose by a
streptavidin bridge. For all conditions tested with protein A,
light scattering was high (> 0.100 within 300 s) and did not
allow to detect IgG deposition at 400 μg mL−1. Protein G
beads provided low light scattering and lower baseline varia-
tion (< 0.030 within 300 s), allowing repeatable on-column
monitoring of IgG attachment to bead surface.
Additionally, protein G is more specific to IgG capture than
protein A, which also binds to human IgM, IgD, and IgAwith
lower affinity. Hence, serum matrix components (including
immunoglobulins belonging to other classes) are not retained
in the protein G column, being immediately flushed to waste.
Finally, human IgG also bind to protein G (association con-
stant between 107 and 1010 M−1) with greater affinity than
protein A [39, 40]. Therefore, protein G-Sepharose 4B was
chosen as solid support. Diameter distribution of those micro-
beads ranges from 45 to 165 μm, provided that the matrix
comprises Sepharose with 4% of cross-linking. The beads
present micro-pores in their structure, which set the molecular
weight cutoff between 6 × 104 and 2 × 107 for globular pro-
teins. Regarding binding features, the solid support contains
2.5 mg of protein G per mL with 2 IgG binding sites per
molecule. Binding affinity was ca. 18 mg of IgG per mL of
solid support.
The study of the bead column packing LOV procedure
(Table 1, routine A) was carried out using non-functionalized
Sepharose CL-4B. To ensure the repeatability of the bead aspi-
ration and packing inside the flow cell, beads were first flushed
Fig. 2 Baseline profile for Sepharose 4B beads with immobilized protein
G or immobilized protein A (flow rate, 1 μL s−1)
and dispersed inside the storage port 1 (Table 1, step II) and then
back aspirated into the holding coil [41] (Table 1, step III).
Several flushing flow rates (1–10 μL s−1) and volumes (1–
10 μL) were tested. Bead dispersion inside the channel of port
1 was achieved by sending 4μL at 3μL s−1. Aspiration flow rate
for bead transfer into the holding coil was set to 5μL s−1 to avoid
the introduction of air bubbles in the system.
Subsequently, experiments to establish the volume of bead
suspension aspirated from port 1 (Table 1, step IV) and sent
for column assembly were carried out, using volumes between
2 and 20 μL. This is an important parameter to evaluate because
the amount of beads sent to the flow cell to pack the column
affects method sensitivity as it will determine the position of the
solid phase with respect to the light beam (Fig. 3, schematic
representation). Hence, after packing the column, a solution con-
taining 300 μg mL−1 of human IgG was propelled through the
column at 1μL s−1 and optical density (OD 280 nm) values were
plotted against volume of beads sent to the flow cell (Fig. 3) as
signal intensity reflects the amount of IgG that gets retained
within the optical path [42]. Bead suspension volumes < 5 μL
did not provide enough material for sensitive IgG retention (Fig.
3, zone A in the graph) and thus OD values were < 0.100. For
volumes between 5 and 10 μL (Fig. 3, zone B in the graph),
small variations on the amount of beads sent into the flow cell
afforded differences on signal intensity. The highest OD values
were obtained for 8 μL (0.250 ± 0.009). At this volume,
the beads occupied the entire optical path as checked visu-
ally and schematically depicted in Fig. 3, scheme B. Larger
volumes (10 to 20 μL) led to lower OD values (< 0.070)
because IgG was mainly retained in the top part of the bead
column, decreasing the amount of IgG in the solid phase
exposed to the light beam (Fig. 3, scheme C). Therefore,
bead volume was set to 8 μL in order to maximize signal
intensity. Moreover, under these conditions, baseline noise
is negligible (ΔOD280 < 0.0003 s
−1) and ca. 200 μg of
solid support is required per analysis.
Sample volume was also tested by injecting 5, 10, 20, and
40μL of IgG at 300μgmL−1. Recoveredmass was 1.6, 2.8, 5.9,
and 10.9 μg, representing relative deviations < 6.5% from the
theoretical value, except for the largest volume. In this case, IgG
mass surpassed the established linear range for response. These
features (including label-free, on-column detection) allow the
operator to perform the evaluation of IgG content in real-time
by assaying different sample volumes, avoiding unnecessary
runs with a consequent reduction in reagents consumption and
generation of waste. In opposition, when samples are analyzed
by microplate ELISA, it is also mandatory to prepare and run
several dilutions of the sample in parallel to overcome matrix
Fig. 3 Optical density (OD
280 nm) corresponding to loading
20 μL of human IgG
(300 μg mL−1) in protein G
bioaffinity columns packed from
different volumes of bead
suspension. Schematic
representation of column
assembly at flow cell upon bead
suspension volume. LS light
source, CCD spectrometer
Fig. 4 μ-BIS signal of a IgG standard solutions (concentration of
standards in μg mL−1, corresponding to 5.0–60 mg mL−1 in undiluted
samples), prepared in PBS + 1.0 μg mL−1 of human serum albumin. b
Human serum samples diluted in PBS at two levels (1:50 and 1:100).
Injection volume was 20 μL
effect and non-specific binding. Hence, this is a clear advantage
of the automated μ-BIS-LOV method.
Figures of merit of μ-BIS-LOV IgG assay
Typical analytical signals obtained for IgG standard solutions are
shown in Fig. 4a, where the time-point 0 s corresponds to the
sample injection point. Signal stabilization is achieved after 75 s
and the average value of OD obtained between 82 and 92 s was
considered for establishing a relation between the OD 280 nm
and IgG concentration in μg mL−1. Calibration curves were
established between 100 and 300 μg mL−1, with a typical equa-
tion of y = 0.749 ± 0.023x + 0.021 ± 0.016, R > 0.9975. For
concentrations above 300μgmL−1, signal increasewas observed
but its relation to concentration was not linear.
The limit of detection (LOD) was calculated as the concen-
tration corresponding to the intercept value of the calibration
curve plus three times the statistics sy/x as an estimate of the
standard deviation [43]. Hence, LOD was 33 μg mL−1, corre-
sponding to 1.7 mg mL−1 in samples diluted 50 times (lowest
dilution factor).
The overall time of analysis was estimated by adding the
time taken by each step of the protocol routines (Table 1).
Routines A, B, and C took 30, 131, and 28 s, respectively.
Sample exchange operation (ca. 60 s) was also considered.
Therefore, the time required for a complete analytical cycle
was 4.1 min, setting the determination rate at 15 h−1.
Therefore, compared to ELISA procedures, time to result
was reduced from several hours to < 5 min.
Precision was estimated for both the lowest (100 μg mL−1)
and the highest (300 μg mL−1) levels of the calibration curve.
Concerning intra-assay precision, four consecutive injections
were carried out affording RSD values < 9.4% (100 μg mL−1)
and < 5.0% (300 μg mL−1). As for inter-assay precision
(n = 3), RSD values found were < 11.7 and < 8.8% for the
lowest and the highest levels, respectively.
The developed method provided a miniaturized label-free
assay with no need for the use of secondary antibodies, en-
zyme conjugates, or revealing agents and, for that reason, the
cost of the overall analysis was decreased around 10 times
when compared to the microplate ELISA. The estimate cost
per analysis is ca. 0.60 € for the μ-BIS-LOVand ca. 6 € for the
commercial microplate ELISA kit.
Analysis of serum samples
Sample preparation consisted on a Bdilute-and-shoot^ proce-
dure. Before analysis, samples were diluted 50 to 200 times to
match the linear range of the calibration curve and also to
circumvent possible matrix effects caused by other serum pro-
teins, providing a determination range of 5.0–60 mg mL−1.
Twenty microliters of diluted sample was required for each
determination. Therefore, the undiluted sample volume
required for analysis was very low (1–6 μL per analysis). In
addition, sample dilution also afforded control of reaction pH
and ionic strength, which is critical to IgG adsorption/
desorption to protein G.
Human serum albumin (HSA) is the most abundant protein
in serum and, thus, it was chosen as a model protein to assess
the possible interference in the μ-BIS measurements. In phys-
iological conditions, HSA is present in human serum at con-
centrations between 35 and 55 mg mL−1 [44–46]. After the
proposed sample dilution (at least 50 times), the average HSA
concentration would be < 1.1 mgmL−1. Hence, HSA presence
up to 1.2 mgmL−1 was evaluated. The signal variation obtain-
ed for a solution containing 250 μg mL−1 of IgG was recorded
in the presence of increasing concentrations of HSA (0.7–
1.2 mg mL−1) and compared to the one obtained when no
HSA was present. Comparing the maximum OD values ob-
tained when the IgG standard is prepared in PBS and in PBS-
HSA, it was observed that the deviation of OD values was
< 5.5%. Furthermore, calculated IgG concentrations were
99.0–107% of the target value. Thus, matrix effect was not
significant for HSA concentrations < 1.2 mg mL−1, account-
ing up to 60 mg mL−1 in undiluted serum.
To confirm the absence of matrix effects, recovery tests
were performed using spiked human serum containing
10.6 mg mL−1 of IgG. Two spiking levels were considered
to simulate two different stages of multiple myeloma devel-
opment: monoclonal gammopathy of undetermined signifi-
cance or MGUS ([IgG] < 30 mg mL−1) and asymptomatic
myeloma ([IgG] > 30 mg mL−1). Thus, serum was spiked to
a final concentration of 17.8 and 40.5 mg mL−1 in IgG.
Recovery values were 101.4 ± 3.4 and 97.8 ± 3.0%, respec-
tively, using dilution factors at two levels (100 to 200 times).
The IgG concentration in the serum of eight individuals
(serum A to H) was determined by μ-BIS-LOV and micro-
plate ELISA kit (Table 2). The typical analytical profiles ob-
tained for serum samples at two levels of dilution (1:50 and
Table 2 IgG
concentration (mg mL−1)
in human serum samples
(mean ± standard
deviation) obtained by μ-
BIS-LOV (Cμ-BIS-LOV)
and the microplate
ELISA kit (CELISA)
Samplea Cμ-BIS-LOV CELISA
Serum A 12.0 ± 0.9 13.0 ± 0.1
Serum B 14.1 ± 1.0 13.8 ± 0.1
Serum C 13.2 ± 0.6 12.9 ± 0.7
Serum D 10.4 ± 1.0 10.2 ± 0.6
Serum E 6.7 ± 0.1 5.5 ± 0.7
Serum F 11.6 ± 1.2 11.9 ± 0.5
Serum G 13.8 ± 0.9 13.2 ± 0.9
Serum H 14.1 ± 1.3 14.8 ± 0.8
a Each va lue cor re sponds to the
mean ± standard deviation (n = 2). Prior
to analysis by μ-BIS-LOV assay and
ELISA, samples were diluted 50 to 100
times and 106 times, respectively
1:100) are provided in Fig. 4b. The results obtained for the
developed label-free method were in good agreement with
those obtained using the ELISA commercial kit. Paired t test
was performed and the |t|calculated value was 0.055 (ttabulated
(P = 0.05; df = 14) = 2.14). Hence, no statistically significant
difference was found for results obtained by the two methods.
Repeatability for sample analysis was also evaluated. The
overall precision (RSD 1.5–10.3%) was comparable to the
microplate ELISA kit (RSD 0.7–12.7%). Additionally, three
samples selected randomly (A, F, and G) were diluted at
1:100 and run in triplicate providing RSD values of 1.9,
8.0, and 10.2%, respectively. Serum sample C was also
diluted at 1:100 and injected five consecutive times with
RSD value < 9.0%.
Conclusions
The μ-BIS-LOV method allows real-time on-column and
label-free determination of total serum IgG under a miniatur-
ized format. Immunoglobulins are separated from the serum
matrix components, followed by their quantification, avoiding
matrix interferences and non-specific binding. The proposed
method provides a rapid, automated, and label-free determi-
nation of these biomarkers with a consequent decrease in the
cost of the analysis, compared to the standard ELISA method.
In addition, no sample pretreatment was required besides di-
lution and reaction conditions were strictly controlled by au-
tomatic handling of solutions, ensuring good repeatability of
the measurements within a short time. Washing steps were not
required because the excess of unbound antibodies and other
proteins was automatically flushed away upon sample perco-
lation through the bead column. Issues concerning sample
carryover and fouling of the solid support were fully eliminat-
ed by discarding and assembling of a new column before each
sample determination. Analytical features proved the method
fit for purpose.
Due to the portability of the equipment and the simplicity
of the procedure, we envision that the proposed method is
suitable for point-of-care testing, overcoming the need for
sample analysis in hospital facilities and providing a fast ana-
lytical readout. Therefore, the developed method provides a
suitable cost-effective and fast alternative for the direct mea-
surement of IgG in serum.
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